• Absence of aneurysm sac growth [ Time Frame: 3, 6 and 12 months ]
  Absence of aneurysm sac growth at 3, 6 and 12 months the end-point at 6 month is the ultimate clinical success rate assessment - growth is determined based on core lab assessments of lateral, frontal and/or longitudinal axis and/or largest diameters
• Intra- and peri-operative complications [ Time Frame: 30 days ]
  Documentation of intra- and peri-operative complications
• serious adverse events, vascular related adverse events and adverse device effects: complications and deaths, re-interventions, aneurysm rupture [ Time Frame: During the Aneufix procedure ]
  Occurrence of serious adverse events, vascular related adverse events and adverse device effects: complications and deaths, re-interventions, aneurysm rupture in the peri operative period.
• Occurrence of general adverse events and adverse device effects [ Time Frame: 1, 3, 6, 12 and 24 months ]
  Safety is assessed based on the nature and severity of observed adverse events
• Rate of re-interventions [ Time Frame: 1, 3, 6 and 12 months ]
  Rate of secondary endovascular or surgical re-interventions
• Rate of aneurysm rupture [ Time Frame: 6 and 12months ]
  Rate of aneurysm rupture will be observed
• Survival rate [ Time Frame: 24 months ]
  Survival throughout the study

• Intraoperative occurrence of complications; [ Time Frame: 24 hours ]
  The serious adverse events occurring during the surgical intervention are registered.
• Serious adverse events, [ Time Frame: 1, 3, 6 and 12 month ]
  Vascular related adverse events and adverse device effects;
• Clinical success rate. [ Time Frame: 3, 6 and 12 months ]
  Absence of aneurysm sac growth at 3, 6 and 12 months, measured by the aneurysm sac diameter on CT scans (clinical success rate at 6 months is the ultimate end-point assessment)
• Peri-operative complications. [ Time Frame: 30 days ]
  Rate of peri-operative complications
• Re-interventions. [ Time Frame: 1, 3, 6 and 12 months ]
  Rate of secondary endovascular or surgical re-interventions
• Aneurysm rupture [ Time Frame: 6 and 12months ]
  Rate of aneurysm rupture
• Survival [ Time Frame: 24 months ]
  Survival throughout the study
• General safety [ Time Frame: 24 months ]
  Safety is assessed based on the nature and severity of observed adverse events

The investigational device is called ANEUFIX, which is a product treating the endoleak by blockage of backflowing blood vessels, i.e. by filling the endoleak void and nidus of feeding artery and exit of existing draining arteries.

ANEUFIX is a polymer that cures rapidly (7 min at 37°C) after injection into the AAA-sac close to the nidus.

• Abdominal Aortic Aneurysm
• Endoleak

Inclusion Criteria:

1. Persistent type II endoleak (more than 6 months post-EVAR or post-embolization procedure); AND
2. Volume of the 'endoleak void' can be estimated upfront; AND
3. An EVAR without circulatory complications (including the absence of an open AMI as judged on existing CT-scan); AND
4. An endoleak confirmed by CT scan in preceding 90 days demonstrating the high likelihood of the isolated nature of the endoleak; AND
5. An aneurysm sac growing in contours after EVAR (per European Guidelines) as documented in the preceding 90 days by means of Echo Doppler (or alternative visualization technique) and based upon sac diameter measurements; AND
6. An aneurysm sac that can be punctured via a translumbar approach; AND
7. Possibility to withhold anti-thrombogenic medication temporarily; AND
8. Ability and willingness to undergo the translumbar procedure under local anesthaesia in a CT scanner; AND
9. Being older than 18 years.

Exclusion Criteria:

1. Patient not able or willing to give written Informed Consent; OR
2. Patient undergoing emergency procedures; OR
3. Patient with traumatic vascular injury; OR
4. Patients with an untreated open endoleak connected AMI (patients can be included if the AMI is or is technically not possible to be coiled prior the Aneufix application); OR
5. Patient with haemostatic disorder (including bleeding disorders) or who is clinically unstable; OR
6. Patient with a too high risk of abdominal sac rupture to allow safe radiological and scanographic assessments; OR
7. Patient who is allergic to contrast media or anticoagulants; OR
8. Patient with renal impairment (eGFR < 30 ml/min); OR
9. Patient with a contra-indication for temporal positioning of a translumbar needle/catheter; OR
10. Patient who is participating in another trial with an investigational drug or medical device, or where a medical device/drug is used outside its labelling and its approved intended use; OR
11. Women of child-bearing potential, OR
12. Patient with a life expectancy of less than 12 months.